<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745106</url>
  </required_header>
  <id_info>
    <org_study_id>PADN1</org_study_id>
    <nct_id>NCT02745106</nct_id>
  </id_info>
  <brief_title>Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy</brief_title>
  <official_title>Randomized Pilot Trial of Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novosibirsk Scientific Research Institute for Circulatory Pathology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novosibirsk Scientific Research Institute for Circulatory Pathology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the technique of non-drug treatment of residual pulmonary hypertension in
      patients with chronic thromboembolic pulmonary hypertension after pulmonary
      thromboendarterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The best strategy of treatment patients with chronic thromboembolic pulmonary hypertension is
      pulmonary thromboendarterectomy. In 5-30% of cases after pulmonary thromboendarterectomy
      residual pulmonary hypertension is persisted. The technique of radiofrequency pulmonary
      artery denervation in patients with idiopathic pulmonary arterial hypertension (type I) is
      known and was assessed during clinical investigation. In this study radiofrequency pulmonary
      artery denervation technique may be applied in patients with residual pulmonary hypertension
      after pulmonary thromboendarterectomy (type IV)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary vascular resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Units - (dyn x sec x cm-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walking distance test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographical sings of right ventricle function - 1</measure>
    <time_frame>12 months</time_frame>
    <description>Fractional area change (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographical sings of right ventricle function - 2</measure>
    <time_frame>12 months</time_frame>
    <description>Tricuspid annular systolic excursion, TAPSE (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary artery pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Pulmonary artery pressure (systolic/diastolic/mean) will be measured by right heart catheterization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>PADN treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:
Ablation catheter
Carto 3, Carto RMT, Stereotaxis
Swan-Ganz catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Sham)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Procedure: Right heart catheterization
Using following device:
- Swan-Ganz catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency pulmonary artery denervation</intervention_name>
    <description>Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.</description>
    <arm_group_label>PADN treatment</arm_group_label>
    <other_name>PADN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation catheter</intervention_name>
    <description>4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.</description>
    <arm_group_label>PADN treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Swan-Ganz catheter for right heart catheterization</intervention_name>
    <description>Standart procedure of right catheterization:
punction of right jugular vein with Seldinger technique, introducer placement
insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.
positioning of swan-ganz catheter in pulmonary artery
direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)
calculating of indirect parameters (pulmonary vascular resistance)</description>
    <arm_group_label>PADN treatment</arm_group_label>
    <arm_group_label>Control (Sham)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of residual pulmonary hypertension in patients after pulmonary
             thromboendarterectomy according to right heart catheterization: mean pulmonary artery
             pressure &gt; 25 mm Hg or pulmonary vascular resistance &gt; 400 dyn x sec x cm-5

        Exclusion Criteria:

          -  no evidence of residual pulmonary hypertension in patients after pulmonary
             thromboendarterectomy (mean pulmonary artery pressure &lt;25 m Hg).

          -  refusal of a patient to participate in the study.

          -  the presence of severe concomitant diseases of the cardiovascular system and lungs,
             leading to pulmonary hypertension

          -  the presence of other severe comorbidities that may result in death within a year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Chernyavskiy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>15 Rechkunovskaya street, Novosibirsk, Russia, 630055</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Romanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Novosibirsk Scientific Research Institute for Circulatory Pathology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evgeny Pokushalov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Novosibirsk Scientific Research Institute for Circulatory Pathology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Edemskiy, MD</last_name>
    <phone>+79139160665</phone>
    <email>aeskander@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalya Novikova, MD</last_name>
    <phone>+79139497601</phone>
    <email>natnov@ngs.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novosibirsk research institute of circulation pathology</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya oblast'</state>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Edemskiy, MD</last_name>
      <phone>+79139160665</phone>
      <email>aeskander@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Novosibirsk Scientific Research Institute for Circulatory Pathology</investigator_affiliation>
    <investigator_full_name>Alexander Edemskiy</investigator_full_name>
    <investigator_title>Principal investigator Alexander Edemskiy</investigator_title>
  </responsible_party>
  <keyword>Chronic thromboembolic pulmonary hypertension, Navigation system, Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

